Phyllis Gardner, M.D.
Partner, Palo Alto- B.S.
- University of Illinois
- M.D.
- Harvard University
Phyllis Gardner, M.D., has over 35 years of experience in academia and the healthcare industry. Dr. Gardner began her academic medical career in 1984 at Stanford University, where she held several positions including Senior Associate Dean for Education and Student Affairs. Dr. Gardner is currently a Professor of Medicine (with tenure) and a member of the Academic Council Committee on Research at Stanford University. From 1994 to 1996, she took a leave of absence as Principal Sciences, Vice President of Research and Head of ALZA Technology Institute, a major drug delivery company. She has conducted extensive research in cell biology, including gene therapy, and is widely published in the fields of cell biology and pharmacology. She has received numerous national awards and honors and has served on the Board of Directors of several public and private companies. Dr. Gardner currently serves as President of the Harvard University Medical Alumni Council and was recently appointed to the Harvard University Medical School Advisory Council on Education.
Essex Woodlands first worked with Dr. Gardner through a joint directorship of Aronex Pharmaceuticals, a Fund IV portfolio company that was acquired by Antigenics, Inc. (NASDAQ: AGEN) in 2002. She was also responsible for the Partnership’s introduction to Rinat Neurosciences, a Genentech spinout in which Essex Woodlands became the lead investor, which was acquired by Pfizer. Her extensive expertise in pharmacology and drug delivery has been invaluable to the Partnership in evaluating technology in this growing segment of the pharmaceutical sector.
Dr. Gardner joined Essex Woodlands as an Adjunct Partner in June 1999 and was promoted to Partner in July 2009.
